FIELD: medicine.
SUBSTANCE: group of inventions relates to pharmacology and therapy. Invention discloses a medicament containing an effective amount of a reversible P2Y12 receptor antagonist with cangrelor effect for treating or preventing pulmonary hypertension in a subject; a medicament based thereon for reducing mortality in a subject with pulmonary hypertension; a medicament based thereon for inhibiting ADP-mediated vasoconstriction of pulmonary arteries and methods for preparing said medicaments (versions).
EFFECT: reduced pulmonary vasoconstriction caused by hypoxia and ADP with cangrelor.
16 cl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREVENTION OF SYSTEMIC PULMONARY BYPASS THROMBOSIS | 2018 |
|
RU2782074C2 |
| COMBINATION THERAPY FOR TREATMENT OF PULMONARY HYPERTENSION | 2017 |
|
RU2763525C2 |
| COMBINATION THERAPY OF PULMONARY HYPERTENSION | 2016 |
|
RU2780758C2 |
| BIOTRANSPLANT AND METHOD FOR TREATMENT OF LUNG HYPERTENSION | 2004 |
|
RU2271817C1 |
| APPLICATION OF ORGANIC COMPOUNDS | 2005 |
|
RU2426532C2 |
| PHARMACEUTICAL COMPOSITION INCLUDING SELECTIVE AGONIST OF IMIDAZOLINE RECEPTOR I1 AND BLOCKER OF ANGIOTENSIN II RECEPTOR | 2004 |
|
RU2362561C2 |
| PRODRUGS OF MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | 2014 |
|
RU2659220C2 |
| THERAPEUTIC APPLICATION OF BONE MORPHOGENETIC PROTEINS | 2015 |
|
RU2733318C2 |
| HYPOTENSIVE COMBINATION OF VALSARTAN AND CALCIUM CANAL BLOCKERS | 1999 |
|
RU2450813C2 |
| METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION AND ISCHEMIC DAMAGE | 2012 |
|
RU2638807C2 |
